Minoxidil Vs Breezula (Clascoterone): How They Compare For Hair Loss
Last reviewed on 8 October 2026. We review our treatment guides every six months to keep them accurate.
Key points
They are both topicals, but they do opposite jobs. Minoxidil and Breezula (the brand name for clascoterone) are both applied to the scalp, but minoxidil stimulates the follicles to grow, while Breezula is designed to block DHT, the hormone that drives male pattern hair loss.
Minoxidil does not touch DHT. It works through other routes, widening blood vessels and prolonging the growth phase of the hair cycle, so it supports hair regardless of the hormonal cause but does not slow the underlying process that shrinks the follicles.
Breezula tackles the cause, locally. Clascoterone sits on the follicle’s androgen receptor so DHT cannot bind, acting only at the scalp and aiming to avoid whole-body effects.
Because they work differently, they are not really rivals. One stimulates growth and the other blocks the hormonal trigger, so in principle they could complement each other rather than compete, much as minoxidil is already paired with the DHT-lowering tablets.
The decisive practical difference: minoxidil is available now, Breezula is not. Minoxidil is a licensed, proven, inexpensive treatment you can buy today, while Breezula, for hair loss, is still in development and not approved.
Breezula’s hair-loss evidence is promising but incomplete. Early studies are encouraging and later-stage trials have been reported, but the full results have not yet been published in peer-reviewed journals.
Neither adds hair or restores a bald scalp. Both support the hair you still have; for bald areas a hair transplant is the only option that adds hair. Which suits you is best decided with a clinician.
Minoxidil and Breezula are both topical treatments you apply to the scalp, which makes it tempting to see them as rivals. In fact they do almost opposite jobs. Minoxidil is a stimulant that encourages the follicles to grow, working through routes that have nothing to do with the hormone behind male pattern hair loss. Breezula (clascoterone) is an anti-androgen that blocks that hormone, DHT, at the scalp. The other crucial difference is availability: minoxidil is a proven treatment you can use today, while Breezula, for hair loss, is still in development.
This guide compares minoxidil and Breezula neutrally: what each is, how they differ, how effective they are, where each stands, who each suits, and how they fit with other treatments. It is general information and not a substitute for advice from a doctor.
The short answer
Minoxidil and Breezula are both applied to the scalp, but they work in completely different ways. Minoxidil is a proven stimulant: it widens blood vessels and prolongs the growth phase of the hair cycle, encouraging follicles to produce thicker, longer hairs, but it does nothing about DHT, the hormone that drives male pattern loss. Breezula is the brand name for clascoterone, a topical anti-androgen that sits on the follicle’s androgen receptor and blocks DHT from acting there, tackling the hormonal cause locally and designed to avoid whole-body effects. Because one stimulates growth and the other blocks the trigger, they are not really competitors, and in principle could be used together. The catch is that Breezula is not yet available for hair loss: clascoterone is approved as a cream for acne, but the hair-loss version is still in development. So, in practice, minoxidil is the proven treatment you can use now, while Breezula is a promising option to watch for the future. Neither, though, can regrow a scalp that is already bald.
What is minoxidil?
Minoxidil is the most widely used topical treatment for hair loss, applied to the scalp as a solution or foam (and sometimes taken as a low-dose tablet). Rather than targeting the hormone behind male pattern loss, it stimulates the follicles directly. As a comprehensive review of minoxidil describes, it "acts through multiple pathways (vasodilator, anti-inflammatory agent, inducer of the Wnt/beta-catenin signaling pathway, an antiandrogen), and may also affect the length of the anagen and telogen phases", and in practice its main effects are widening blood vessels around the follicle and prolonging the growth phase, so hairs grow for longer and come through thicker. The same review notes that "topical minoxidil causes hair regrowth in both frontotemporal and vertex areas". Although that list mentions a minor anti-androgen action, minoxidil is not used or relied upon as a DHT blocker; it is a stimulant, which is why it is often combined with a treatment that does tackle DHT. Our guide on minoxidil for hair loss covers it in detail, and finasteride versus minoxidil compares it with the first-line DHT-lowering tablet.
What is Breezula (clascoterone)?
Breezula is the brand name under development for clascoterone used on the scalp for hair loss. Unlike minoxidil, it works directly against DHT. As a narrative review of clascoterone explains, "clascoterone cream is the first topical androgen receptor inhibitor approved by the U.S. Food and Drug Administration (FDA) for the treatment of acne vulgaris", and it works "by binding to androgen receptors in a manner competitive with DHT", blocking the signalling that DHT would otherwise trigger at the follicle. Crucially, "topical administration of clascoterone enables selective targeting of cutaneous androgen receptors, while its rapid metabolic inactivation to cortexolone, an inactive metabolite, minimizes the potential for systemic adverse effects", which is the appeal of a scalp anti-androgen: to tackle the hormonal cause locally while avoiding whole-body effects. For hair loss specifically it is not yet approved; our guide on Breezula (clascoterone) for hair loss covers where it stands.
Which is more effective for hair loss?
Minoxidil has the far stronger evidence, because it is established and proven while Breezula is not yet available. Minoxidil has decades of use and good trial support for growing hair at the crown and front, as the minoxidil review sets out. Clascoterone for hair loss is promising but early: the clascoterone review notes it "has emerged as a promising candidate for the treatment of androgenetic alopecia", while being clear that "emerging but still incomplete data suggest potential applications in androgenetic alopecia", and that "in phase 2 studies, clascoterone treatment showed favorable outcomes in measures such as scalp sebometric measurement, hair diameter, follicular density, and pull test/wash test".
Importantly, the later-stage hair-loss trials have not yet been independently published. The review notes that the pivotal phase 3 AGA programme "was reported to be completed in 2025", but that "the complete results of these trials have not been published in peer-reviewed journals and are available only through sponsor-issued announcements", and that "because these findings have not undergone independent scientific evaluation, they cannot be presented as established evidence". So the honest position is that minoxidil is proven and available, while Breezula is a promising but still unproven and unapproved option for hair loss. The two are also not directly comparable, because they do different jobs: one grows hair, the other would protect it from DHT.
Minoxidil vs Breezula: how do they compare?
Both are topicals, but they target opposite things, and they differ crucially in availability:
What they are: both are applied to the scalp. Minoxidil is a topical (or low-dose oral) stimulant; Breezula (clascoterone) is a topical anti-androgen.
How they work: minoxidil stimulates the follicles, widening local blood vessels and prolonging the growth phase, without affecting DHT; clascoterone blocks DHT from binding the follicle’s androgen receptor, so it tackles the hormonal cause rather than stimulating growth.
What they tackle: minoxidil supports hair regardless of the cause but does not slow the underlying process; clascoterone targets that underlying process locally but does not itself stimulate new growth.
Availability: minoxidil is available for hair loss now, licensed and inexpensive; clascoterone is approved only as an acne cream, and the hair-loss version is still in development, not yet approved.
Evidence: minoxidil has decades of use and good trial support; clascoterone for hair loss has promising but incomplete data, with the key late-stage results not yet peer-reviewed.
Side effects: minoxidil is generally well tolerated, with scalp irritation and some shedding when starting the most common issues, and is applied daily; clascoterone’s topical, local design is intended to keep side effects low, though its long-term hair-loss safety is still being established.
Rivals or partners: because one grows hair and the other would block the hormonal trigger, they are complementary rather than competing, and could in principle be used together, much as minoxidil is already combined with DHT-lowering tablets.
What neither does: neither adds new hair or restores a bald area, so both are for supporting the hair you still have rather than replacing hair that is gone.
Which is right for you?
In practical terms today, minoxidil is the option you can actually use: it is proven, licensed, inexpensive and easy to apply, and it stimulates the follicles to grow thicker, longer hair. Breezula is not currently available for hair loss, so it is not a choice you can make right now, however appealing a scalp anti-androgen that tackles the hormonal cause locally might sound. Clascoterone is the most advanced treatment of that local anti-androgen kind, so it is well worth watching, but it remains promising rather than proven, and unapproved for hair loss. The more useful way to think about them is not as a choice between two rivals but as two different jobs: minoxidil grows hair, while a treatment like Breezula would protect it from DHT, and many people ultimately benefit from doing both, which today usually means minoxidil alongside a DHT-lowering tablet.
Neither, in any case, suits someone whose loss is advanced or whose follicles are already gone, because both only support hair that is still there. Because these are different tools for different parts of the problem, and Breezula is still investigational for hair loss, the sensible step is to discuss your options with a clinician, who can set out what is proven and available now and keep you informed as newer treatments reach approval.
Can they be combined with other treatments?
For now, combining minoxidil and Breezula is largely theoretical, because Breezula is not yet available for hair loss. In principle it is an appealing pairing, because minoxidil stimulates growth while clascoterone would block the hormonal trigger, so the two attack the problem at different points and should not overlap. That is exactly the logic behind today’s standard combination: minoxidil is routinely paired with a DHT-lowering tablet such as finasteride, which we compare in our guide on finasteride versus minoxidil. The finasteride-and-Breezula and dutasteride-and-Breezula comparisons are covered in our guides on finasteride versus Breezula and dutasteride versus Breezula.
Neither minoxidil nor Breezula can restore hair that is already gone. Where loss is more advanced, a hair transplant is a separate option that redistributes your own permanent hair, and treatments like minoxidil are often used around a transplant to protect and support the result. The key point is that these are treatments to keep and support the hair you have, used as part of a wider plan, not a cure.
The bottom line
Minoxidil and Breezula are both topicals applied to the scalp, but they do opposite jobs. Minoxidil is a proven stimulant that encourages the follicles to grow, working through routes that have nothing to do with DHT, while Breezula (clascoterone) is a topical anti-androgen that blocks DHT, the hormone behind male pattern hair loss, at the scalp. Minoxidil is licensed, inexpensive and available now; Breezula is a promising local anti-androgen whose appeal is tackling the hormonal cause with minimal whole-body effect, but for hair loss it is still in development, not approved, and its late-stage evidence has not yet been independently published. Neither adds hair or restores a bald area.
If you are choosing a treatment today, minoxidil is the proven, available option, while Breezula is one to watch for the future. But the better framing is that they are not really rivals: minoxidil grows hair, and a treatment like Breezula would protect it from DHT, so many people may eventually benefit from both. A clinician can help you decide what suits your hair loss now, usually minoxidil with or without a DHT-lowering tablet, and how newer treatments might fit in once they are approved.
Frequently asked questions
Is Breezula better than minoxidil for hair loss?
It is not really the right question, and in practical terms it is moot for now because Breezula is not yet available for hair loss. The two do different jobs: minoxidil stimulates the follicles to grow, while Breezula blocks DHT, the hormone that drives the loss. Minoxidil is proven and available; clascoterone, the drug in Breezula, is a promising topical anti-androgen whose hair-loss data are still incomplete and whose key late-stage results have not yet been peer-reviewed. So minoxidil is the established option you can use, while Breezula is a promising one to watch, and the two may ultimately work best together rather than as alternatives.
Is Breezula available for hair loss?
Not yet. Clascoterone, the active drug, is approved as a cream for acne, but the higher-strength scalp solution developed for hair loss, Breezula, is still in clinical development and has not been approved for hair loss in the UK or elsewhere. Later-stage trials have been reported by the company, but the full results have not yet been published in peer-reviewed journals, and an approval decision has not been made. So you cannot currently get Breezula as a hair-loss treatment, whereas minoxidil is available over the counter.
What is the difference between minoxidil and Breezula?
Both are applied to the scalp, but they work in opposite ways. Minoxidil is a stimulant: it widens blood vessels around the follicle and prolongs the growth phase of the hair cycle, encouraging thicker, longer hairs, but it does not affect DHT, the hormone behind male pattern loss. Breezula (clascoterone) is an anti-androgen: it sits on the follicle’s androgen receptor and blocks DHT from acting there, tackling the hormonal cause locally. So minoxidil grows hair, while Breezula would protect it from the hormone; and minoxidil is available now, while Breezula is still in development for hair loss.
Can you use minoxidil and Breezula together?
Not at the moment, because Breezula is not yet available for hair loss. In principle, though, it would be a sensible pairing: minoxidil stimulates growth while clascoterone would block DHT, so the two work at different points and should complement rather than clash. That is the same logic behind today’s standard combination of minoxidil with a DHT-lowering tablet such as finasteride. If and when Breezula is approved, using it alongside minoxidil may well be an option, but that would be a decision to make with a clinician.
Get back to Great Hair
in 3 Easy Steps:
01
Arrange Free Consultation
Speak to one of our specialist consultants for expert advice on our range of different hair loss treatments
02
Book Your Procedure
Place a deposit to reserve a time slot at one of the My Hair UK clinics across the UK
03
Attend Your Surgery
Arrive on the day and our specialist surgical team will look after your every need
What People Say About Us
Read our independent My Hair UK Reviews on Reviews.io
The Surgical Team
The surgical team is what makes the difference on the day. The clinics’ five surgeons are all GMC-registered, with a minimum of 1,000 FUE hair transplant procedures each to their name. Between them the team handles complex cases, including Afro-textured and women’s hair transplants, hairline design and lowering, and revision work.
Manchester clinic
• Dr Khawaja Masood Munir: GMC 6122581.
8+ years’ experience, 1,400+ hair transplant surgeries.
• Dr Haider Gillani: GMC 8030796.
1,000+ procedures, with specific expertise in complex cases requiring detailed anatomical understanding.
London (Harrow) clinic
• Dr Mahdi Alosert: GMC 6168297.
20+ years’ clinical experience. Specialist in Afro-Caribbean hair and hairline lowering.
• Dr Shuaib Mir: GMC 7567898.
1,200+ hair transplant cases. BAAPS plastic surgery and RCS anatomy training.
• Dr Zakar Rafiq: GMC 6164032.
MBBS and BSc (Hons) from Imperial College London. Associate Member of the International Society of Hair Restoration Surgery (ISHRS).
You can meet the surgeon who will perform your procedure at your free consultation.